Emerging Markets Earnings Roundup: BMS, Pfizer (Part 2)
This article was originally published in PharmAsia News
Executive Summary
BMS elaborated on its plans to ease out of the emerging market explosion in demand for diabetes treatments as it moves to develop new therapies in immune-oncology. Pfizer saw China revenues rise smartly in the fourth quarter and Lipitor sales standout in emerging markets.